Sign In
Buy AMT
$182.24
-3.29 (-1.77%)
At Close: Jun 03, 2026
American Tower Stock Gains on Q1 AFFO Beat, Revenues Rise Y/Y
02:15pm, Tuesday, 29'th Apr 2025
AMT's Q1 results reflect a year-over-year rise in revenues, led by property and service operations segment revenues. Strong organic tenant billing growth aids results.
Compared to Estimates, American Tower (AMT) Q1 Earnings: A Look at Key Metrics
12:00pm, Tuesday, 29'th Apr 2025
While the top- and bottom-line numbers for American Tower (AMT) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics com
American Tower Corporation (AMT) Q1 2025 Earnings Call Transcript
11:58am, Tuesday, 29'th Apr 2025
American Tower Corporation (NYSE:AMT ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Adam Smith - Senior Vice President, Investor Relations and FP&A Steve Vondran - P
Baron Real Estate Fund Q1 2025 Top Contributors And Detractors
09:45am, Tuesday, 29'th Apr 2025
Welltower Inc. outperformed due to its strong senior housing portfolio, cyclical and secular growth prospects, and strategic acquisition of Amica. American Tower Corporation showed solid performance d
American Tower beats quarterly revenue estimate on strong telecom infrastructure leasing demand
08:15am, Tuesday, 29'th Apr 2025
Wireless infrastructure provider American Tower on Tuesday beat the first-quarter revenue estimate, driven by steady demand for its leasing business.
American Tower Corporation Reports First Quarter 2025 Financial Results
07:00am, Tuesday, 29'th Apr 2025
BOSTON--(BUSINESS WIRE)--American Tower Corporation (NYSE: AMT) today reported financial results for the quarter ended March 31, 2025. Steven Vondran, American Tower's Chief Executive Officer, stated,
Crown Castle Vs. American Tower: A Battle Of The Tower REITs
05:55pm, Monday, 28'th Apr 2025
American Tower (AMT) is favored over Crown Castle (CCI) due to a better balance sheet, and stronger FFO growth relative to price growth. CCI's higher dividend yield is unsustainable, with a significan
Curious about American Tower (AMT) Q1 Performance? Explore Wall Street Estimates for Key Metrics
10:21am, Thursday, 24'th Apr 2025
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for American Tower (AMT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for
The State Of REITs: April 2025 Edition
12:22pm, Monday, 21'st Apr 2025
REITs finished the first quarter of 2025 in the red (-3.36%) with a brutal -4.92% average total return in March. Large cap (-2.04%) and mid cap REITs (-2.63%) saw modest losses, but small caps (-4.16%
uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130
01:56am, Monday, 21'st Apr 2025
uniQure's AMT-130 gene therapy for Huntington's Disease shows promising trial data, leading to significant stock price increases and potential for FDA accelerated approval. QURE's stock has seen volat
Powell On The Hot Seat
09:00am, Sunday, 20'th Apr 2025
US equity markets steadied this past week while bond markets rallied as investors parsed a surprisingly solid slate of economic data and a decent start to corporate earnings season. Early week gains w
Don't Put All Of Your REIT Eggs In One Basket
07:00am, Sunday, 20'th Apr 2025
Reflecting on past financial losses, I emphasize the importance of diversification to mitigate risks, as exemplified by my own experience with real estate investments. I advocate for a diversified inv
uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting
08:31am, Saturday, 19'th Apr 2025
uniQure's AMT-130 gene therapy showed an 80% slowing of Disease progression in Huntington's Disease patients in a phase 1/2 study. Financially strong with $448 million in cash, uniQure can fund operat
Ports In The Storm: 3 REITs That Are Up Year-To-Date
08:15am, Thursday, 17'th Apr 2025
REITs are not as heavily impacted by the trade war. Many are strongly outperforming in this environment. I present three safe havens that should thrive, regardless of what happens next with this trade
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease
07:17am, Thursday, 17'th Apr 2025
~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~
